The global leuprolide acetate market is expected to grow at a significant CAGR during the forecast period (2021-2027). The major factor contributing to the growth of the global leuprolide acetate market includes the rising prevalence of prostate cancer and uterine fibroid. According to the World Health Organization (WHO), in 2020, 10 million people died due to cancer, and prostate cancer accounted for the 1.41 million cases globally. According to the study published by Elsevier Ltd. on behalf of Reproductive Healthcare Ltd., in 2017, uterine fibroids are clinically apparent in only 40% of women aged 40 years and over. The incidence of leiomyomas is up to three-fold greater in black women.

Leuprolide is a synthetic 9-residue peptide analog of gonadotropin-releasing hormone (GnRH). It is intended for the palliative treatment of prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. Leuprolide has a greater half-life as compared to the endogenous GnRH due to the single D-amino acid (D-leucyl) residue present in the structure. It acts by binding GnRH receptors and inducing downregulation of the sex steroids and gonadotropin hormone. There are several medications available for leuprolide including Eligard, Fensolvi, Lupaneta, Lupron, Viadur, Zeulide Depot, and others. The approved leuprolide was Lupon by Abbvie Endocrine Inc. in 1985. 

The key players contributing to the growth of the global leuprolide acetate market by adopting various strategies such as product launches and developments, mergers and acquisition, partnerships, and agreements, include TOLMAR Pharmaceuticals, Varian Pharmed, avenit AG, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Livzon Pharmaceutical Group Co., Ltd., among others. For instance, in May 2021, Camcevi (leuprolide) by Foresee Pharmaceuticals received the US FDA approval for the treatment of patients with advanced prostate cancer. Camcevi is a ready-to-use subcutaneous depot formulation. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Product Type

o By Application

o By End-user

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- TOLMAR Pharmaceuticals, Varian Pharmed, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Livzon Pharmaceutical Group Co., Ltd., among others.
  

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Leuprolide Acetate Market- Segmentation

By Product Type

• Intramuscular Injection
• Subcutaneous Injection

By Application

• Prostate cancer
• Precocious
• Uterine fibroid
• Others

By End-User

• Hospitals
• Clinic
• Others

Global Leuprolide Acetate Market - Segmentation by region